An observational time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease: results from three European countries

[1] Coleman RE(2006)Clinical features of metastatic bone disease and risk of skeletal morbidity Clin Cancer Res 12 6243s-6249s

[2] Coleman RE(2001)Metastatic bone disease: clinical features, pathophysiology and treatment strategies Cancer Treat Rev 27 165-176

[3] Parker C(2013)Alpha emitter radium-223 and survival in metastatic prostate cancer N Engl J Med 369 213-223

[4] Nilsson S(2003)The multidisciplinary approach to bone metastases Oncology (Williston Park) 17 845-857

[5] Heinrich D(2015)Burden of skeletal-related events in prostate cancer: unmet need in pain improvement Support Care Cancer 23 237-247

[6] Helle SI(2008)Impact of skeletal complications on patients’ quality of life, mobility, and functional independence Support Care Cancer 16 879-889

[7] O’Sullivan JM(2016)Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases Support Care Cancer 24 1327-1337

[8] Blum RH(2005)The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer Ann Oncol 16 579-584

[9] Novetsky D(2016)Health resource utilization associated with skeletal-related events: results from a retrospective European study Eur J Health Econ 17 711-721

[10] Shasha D(2014)Health resource utilization associated with skeletal-related events in patients with bone metastases: results from a multinational retrospective-prospective observational study—a cohort from 4 European countries J Bone Oncol 3 40-48

[1] Coleman RE(2006)Clinical features of metastatic bone disease and risk of skeletal morbidity Clin Cancer Res 12 6243s-6249s

[2] Coleman RE(2001)Metastatic bone disease: clinical features, pathophysiology and treatment strategies Cancer Treat Rev 27 165-176

[3] Parker C(2013)Alpha emitter radium-223 and survival in metastatic prostate cancer N Engl J Med 369 213-223

[4] Nilsson S(2003)The multidisciplinary approach to bone metastases Oncology (Williston Park) 17 845-857

[5] Heinrich D(2015)Burden of skeletal-related events in prostate cancer: unmet need in pain improvement Support Care Cancer 23 237-247

[6] Helle SI(2008)Impact of skeletal complications on patients’ quality of life, mobility, and functional independence Support Care Cancer 16 879-889

[7] O’Sullivan JM(2016)Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases Support Care Cancer 24 1327-1337

[8] Blum RH(2005)The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer Ann Oncol 16 579-584

[9] Novetsky D(2016)Health resource utilization associated with skeletal-related events: results from a retrospective European study Eur J Health Econ 17 711-721

[10] Shasha D(2014)Health resource utilization associated with skeletal-related events in patients with bone metastases: results from a multinational retrospective-prospective observational study—a cohort from 4 European countries J Bone Oncol 3 40-48